Bristol Myers Squibb Receives Full FDA Approval for Breyanzi in Follicular Lymphoma

Bristol Myers Squibb today announced that the FDA has converted the accelerated approval of Breyanzi (lisocabtagene maraleucel) to full approval for the treatment of adults with relapsed or refractory follicular lymphoma who have received two or more prior lines of therapy. The conversion was based on long-term follow-up data from the TRANSCEND FL trial demonstrating sustained complete response rates. This full approval reinforces Breyanzi as a highly effective treatment option for relapsed/refractory follicular lymphoma.